Inhibitors of the transactivation domain of androgen receptor as a therapy for prostate cancer

被引:2
|
作者
Obst, Jon K. [1 ]
Tien, Amy H. [1 ]
Setiawan, Josie C. [1 ]
Deneault, Lauren F. [1 ]
Sadar, Marianne D. [1 ]
机构
[1] BC Canc Res Inst, Dept Genome Sci, BC Canc, Vancouver, BC V5Z 1L3, Canada
基金
美国国家卫生研究院;
关键词
Prostate cancer; Transactivation domain; Androgen receptor; Small molecules; Castration; Non-castrated; N-TERMINAL DOMAIN; SMALL-MOLECULE INHIBITOR; DEPRIVATION THERAPY; ACTIVATION FUNCTION-1; AR COREGULATORS; CASTRATION; RESISTANT; ENZALUTAMIDE; MONOTHERAPY; MECHANISMS;
D O I
10.1016/j.steroids.2024.109482
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The androgen receptor (AR) is a modular transcription factor which functions as a master regulator of gene expression. AR protein is composed of three functional domains; the ligand-binding domain (LBD); DNA-binding domain (DBD); and the intrinsically disordered N-terminal transactivation domain (TAD). AR is transactivated upon binding to the male sex hormone testosterone and other androgens. While the AR may tolerate loss of its LBD, the TAD contains activation function-1 (AF-1) that is essential for all AR transcriptional activity. AR is frequently over-expressed in most prostate cancer. Currently, androgen deprivation therapy (ADT) in the form of surgical or chemical castration remains the standard of care for patients with high risk localized disease, advanced and metastatic disease, and those patients that experience biochemical relapse following definitive primary treatment. Patients with recurrent disease that receive ADT will ultimately progress to lethal metastatic castration-resistant prostate cancer. In addition to ADT not providing a cure, it is associated with numerous adverse effects including cardiovascular disease, osteoporosis and sexual dysfunction. Recently there has been a renewed interest in investigating the possibility of using antiandrogens which competitively bind the AR-LBD without ADT for patients with hormone sensitive, non-metastatic prostate cancer. Here we describe a class of compounds termed AR transactivation domain inhibitors (ARTADI) and their mechanism of action. These compounds bind to the AR-TAD to inhibit AR transcriptional activity in the absence and presence of androgens. Thus these inhibitors may have utility in preventing prostate cancer growth in the non-castrate setting.
引用
收藏
页数:7
相关论文
共 50 条
  • [1] Androgen receptor inhibitors in treating prostate cancer
    Cole, Ryan N.
    Fang, Qinghua
    Matsuoka, Kanako
    Wang, Zhou
    ASIAN JOURNAL OF ANDROLOGY, 2025, 27 (02): : 144 - 155
  • [2] Bipolar Androgen Therapy Followed by Androgen Receptor Inhibition as Sequential Therapy for Prostate Cancer
    Denmeade, Samuel R.
    Sena, Laura A.
    Wang, Hao
    Antonarakis, Emmanuel S.
    Markowski, Mark C.
    ONCOLOGIST, 2023, 28 (06) : 465 - 473
  • [3] A novel inducible transactivation domain in the androgen receptor:: implications for PRK in prostate cancer
    Metzger, E
    Müller, JM
    Ferrari, S
    Buettner, R
    Schüle, R
    EMBO JOURNAL, 2003, 22 (02) : 270 - 280
  • [4] Androgen receptor (AR) heterogeneity in prostate cancer and therapy resistance
    Jamroze, Anmbreen
    Chatta, Gurkamal
    Tang, Dean G.
    CANCER LETTERS, 2021, 518 : 1 - 9
  • [5] Differential transactivation by the androgen receptor in prostate cancer cells
    Snoek, R
    Bruchovsky, N
    Kasper, S
    Matusik, RJ
    Gleave, M
    Sato, N
    Mawji, NR
    Rennie, PS
    PROSTATE, 1998, 36 (04) : 256 - 263
  • [6] Androgen receptor plasticity and its implications for prostate cancer therapy
    Snow, Oliver
    Lallous, Nada
    Singh, Kriti
    Lack, Nathan
    Rennie, Paul
    Cherkasov, Artem
    CANCER TREATMENT REVIEWS, 2019, 81
  • [7] Androgen receptor antagonists for prostate cancer therapy
    Helsen, Christine
    Van den Broeck, Thomas
    Voet, Arnout
    Prekovic, Stefan
    Van Poppel, Hendrik
    Joniau, Steven
    Claessens, Frank
    ENDOCRINE-RELATED CANCER, 2014, 21 (04) : T105 - T118
  • [8] Immune Modulation in Prostate Cancer Patients Treated with Androgen Receptor (AR)-Targeted Therapy
    Conteduca, Vincenza
    Caffo, Orazio
    Scarpi, Emanuela
    Sepe, Pierangela
    Galli, Luca
    Fratino, Lucia
    Maines, Francesca
    Chiuri, Vincenzo Emanuele
    Santoni, Matteo
    Zanardi, Elisa
    Massari, Francesco
    Toma, Ilaria
    Lolli, Cristian
    Schepisi, Giuseppe
    Sbrana, Andrea
    Kinspergher, Stefania
    Cursano, Maria Concetta
    Casadei, Chiara
    Modonesi, Caterina
    Santini, Daniele
    Procopio, Giuseppe
    De Giorgi, Ugo
    JOURNAL OF CLINICAL MEDICINE, 2020, 9 (06) : 1
  • [9] Targeting the androgen receptor and overcoming resistance in prostate cancer
    Einstein, David J.
    Arai, Seiji
    Balk, Steven P.
    CURRENT OPINION IN ONCOLOGY, 2019, 31 (03) : 175 - 182
  • [10] Allosteric alterations in the androgen receptor and activity in prostate cancer
    Uo, Takuma
    Plymate, Stephen R.
    Sprenger, Cynthia C.
    ENDOCRINE-RELATED CANCER, 2017, 24 (09) : R335 - R348